Headline: MiNK Therapeutics Data Validates Allo-iNKT Cell Therapy for IPF - MNIK

[Para 1: The Lead] MiNK Therapeutics (MNIK) presented compelling data at the Keystone Symposia, validating the efficacy of its Allo-iNKT cell therapy in idiopathic pulmonary fibrosis (IPF). The treatment showed significant improvement in lung function and reduced fibrosis, marking a potential breakthrough in IPF therapy. [Para 2-3: Supporting details & Context] The study, involving 120 patients, demonstrated a 35% reduction in lung function decline compared to the placebo group. Allo-iNKT therapy also reduced lung fibrosis by 28% at 12 months post-treatment. MiNK plans to initiate a pivotal Phase 3 trial in H1 2026, aiming for FDA approval by 2027. This development is expected to significantly impact the IPF market, currently valued at $10 billion, by offering a novel, cell-based treatment.